These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 31155415)

  • 1. Safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine lacking NS1.
    Nicolodi C; Groiss F; Kiselev O; Wolschek M; Seipelt J; Muster T
    Vaccine; 2019 Jun; 37(28):3722-3729. PubMed ID: 31155415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1.
    Mössler C; Groiss F; Wolzt M; Wolschek M; Seipelt J; Muster T
    Vaccine; 2013 Dec; 31(52):6194-200. PubMed ID: 24183981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.
    Pitisuttithum P; Boonnak K; Chamnanchanunt S; Puthavathana P; Luvira V; Lerdsamran H; Kaewkungwal J; Lawpoolsri S; Thanachartwet V; Silachamroon U; Masamae W; Schuetz A; Wirachwong P; Thirapakpoomanunt S; Rudenko L; Sparrow E; Friede M; Kieny MP
    Lancet Infect Dis; 2017 Aug; 17(8):833-842. PubMed ID: 28533093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines.
    Wang P; Zheng M; Lau SY; Chen P; Mok BW; Liu S; Liu H; Huang X; Cremin CJ; Song W; Chen Y; Wong YC; Huang H; To KK; Chen Z; Xia N; Yuen KY; Chen H
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1.
    Wacheck V; Egorov A; Groiss F; Pfeiffer A; Fuereder T; Hoeflmayer D; Kundi M; Popow-Kraupp T; Redlberger-Fritz M; Mueller CA; Cinatl J; Michaelis M; Geiler J; Bergmann M; Romanova J; Roethl E; Morokutti A; Wolschek M; Ferko B; Seipelt J; Dick-Gudenus R; Muster T
    J Infect Dis; 2010 Feb; 201(3):354-62. PubMed ID: 20039806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a dual-protective live attenuated vaccine against H5N1 and H9N2 avian influenza viruses by modifying the NS1 gene.
    Choi EH; Song MS; Park SJ; Pascua PN; Baek YH; Kwon HI; Kim EH; Kim S; Jang HK; Poo H; Kim CJ; Choi YK
    Arch Virol; 2015 Jul; 160(7):1729-40. PubMed ID: 25959557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza.
    Steel J; Lowen AC; Pena L; Angel M; Solórzano A; Albrecht R; Perez DR; García-Sastre A; Palese P
    J Virol; 2009 Feb; 83(4):1742-53. PubMed ID: 19073731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preclinical studies of live intranasal H5N1 influenza vaccine with the deleted HS1 gene].
    Romanovskaia-Roman'ko EA; Ferko B; Vyshemirskiĭ OI; Romanova IuR; Krenn B; Muster T; Grudinin MP; Lapin BA; Egorov AIu; Kiselev OI
    Vopr Virusol; 2011; 56(6):19-22. PubMed ID: 22359944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine.
    Rudenko L; Naykhin A; Donina S; Korenkov D; Petukhova G; Isakova-Sivak I; Losev I; Stukova M; Erofeeva M; Nikiforova A; Power M; Flores J
    Hum Vaccin Immunother; 2015; 11(12):2839-48. PubMed ID: 26697973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1.
    Krenn BM; Egorov A; Romanovskaya-Romanko E; Wolschek M; Nakowitsch S; Ruthsatz T; Kiefmann B; Morokutti A; Humer J; Geiler J; Cinatl J; Michaelis M; Wressnigg N; Sturlan S; Ferko B; Batishchev OV; Indenbom AV; Zhu R; Kastner M; Hinterdorfer P; Kiselev O; Muster T; Romanova J
    PLoS One; 2011 Apr; 6(4):e18577. PubMed ID: 21490925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A live attenuated H5N2 prime- inactivated H5N1 boost vaccination induces influenza virus hemagglutinin stalk specific antibody responses.
    Kongchanagul A; Samnuan K; Wirachwong P; Surichan S; Puthavathana P; Pitisuttithum P; Boonnak K
    Vaccine; 2020 Jan; 38(4):852-858. PubMed ID: 31708176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-clade protective immune responses of NS1-truncated live attenuated H5N1 avian influenza vaccines.
    Shi S; Chen S; Han W; Wu B; Zhang X; Tang Y; Wang X; Zhu Y; Peng D; Liu X
    Vaccine; 2016 Jan; 34(3):350-7. PubMed ID: 26638027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial.
    Howard LM; Hoek KL; Goll JB; Samir P; Galassie A; Allos TM; Niu X; Gordy LE; Creech CB; Prasad N; Jensen TL; Hill H; Levy SE; Joyce S; Link AJ; Edwards KM
    PLoS One; 2017; 12(1):e0167488. PubMed ID: 28099485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.
    van der Velden MV; Geisberger A; Dvorak T; Portsmouth D; Fritz R; Crowe BA; Herr W; Distler E; Wagner EM; Zeitlinger M; Sauermann R; Stephan C; Ehrlich HJ; Barrett PN; Aichinger G
    Clin Vaccine Immunol; 2014 Jun; 21(6):867-76. PubMed ID: 24739978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
    Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
    Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
    Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
    JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults.
    Karron RA; Talaat K; Luke C; Callahan K; Thumar B; Dilorenzo S; McAuliffe J; Schappell E; Suguitan A; Mills K; Chen G; Lamirande E; Coelingh K; Jin H; Murphy BR; Kemble G; Subbarao K
    Vaccine; 2009 Aug; 27(36):4953-60. PubMed ID: 19540952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
    Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
    Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans.
    Overton ET; Goepfert PA; Cunningham P; Carter WA; Horvath J; Young D; Strayer DR
    Vaccine; 2014 Sep; 32(42):5490-5. PubMed ID: 25128802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.